What happened with COYA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Coya Therapeutics is a clinical-stage biotechnology company developing treatments that help immune cells restrain inflammation. Its approach aims to restore the function of regulatory T cells, known as Tregs. Its most advanced candidate, COYA 302, combines low-dose interleukin-2 with another biologic and is being developed for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. None of its candidates is approved for commercial sale.
Dr. Reddy’s Laboratories is its key commercial partner and source of collaboration revenue. Coya conducts clinical development of COYA 302 and seeks U.S. approval for ALS, while Dr. Reddy’s holds exclusive commercialization rights for ALS in the United States, Canada, the European Union and the United Kingdom. Dr. Reddy’s pays Coya for those rights and for achieving development milestones; future payments also depend on sales milestones and royalties if the product reaches market. Licensing milestones account for most collaboration revenue, with research and development services contributing the rest.
Coya also relies on Dr. Reddy’s to develop and supply a component of COYA 302. It funds operations through share sales and partner payments, and needs substantial additional capital to continue development. Product-sales income depends on successful clinical development, regulatory approval and its partner’s commercialization efforts.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Coya depends on Dr. Reddy’s both to supply the proposed abatacept biosimilar in COYA 302 and to commercialize the ALS treatment under licenses that pay Coya milestones and royalties. Watch its development of that component and preparations to bring COYA 302 to market; Coya handles the combination’s clinical development and U.S. ALS approval application.
NeuroSense Therapeutics is pursuing the same ALS patients as Coya, with oral combination treatment PrimeC versus Coya’s injectable combination biologic COYA 302. Its PrimeC Phase 2b testing and planned pivotal Phase 3 study are the developments to watch for this rivalry.
Clene’s lead drug candidate CNM-Au8 competes with Coya’s COYA 302 for future use by ALS patients. Watch the ALS development of this gold nanocrystal suspension, rather than Clene’s separate dietary-supplement sales.
MediciNova’s ALS drug development competes with Coya’s COYA 302 for future treatment adoption. It has no marketing or sales capabilities and expects commercial partners to bring its drugs to market, so ALS development and commercialization partnerships are the relevant news for Coya holders.
Nektar Therapeutics competes with Coya’s approach to restoring immune tolerance by developing IL-2-based drugs that enhance regulatory T cells. Its immune-modulating drug development for autoimmune disease is the relevant comparison, rather than a direct ALS product rivalry.
Cue Biopharma’s CUE-400 programs compete with Coya’s biologics platform by using IL-2 signaling to promote regulatory T cells and immune tolerance. Watch CUE-400 development within Cue’s injectable treatments for autoimmune and inflammatory diseases, rather than its separate oncology programs.
HCW Biologics’ HCW9302 and Coya’s low-dose IL-2 platform both aim to activate regulatory T cells to suppress inflammation. HCW9302’s development for injection or Treg cell therapy is the relevant comparison; HCW’s disclosed Wugen license revenue comes from separate cancer cell-therapy programs.
Amylyx Pharmaceuticals remains a prospective ALS rival to Coya’s COYA 302 through AMX0114, despite its growing endocrine focus. Watch AMX0114 development rather than past ALS sales: Amylyx began withdrawing RELYVRIO and ALBRIOZA from the U.S. and Canadian markets in 2024 and reported no product revenue in 2025.
Biogen already markets QALSODY for a genetic subset of ALS patients, overlapping part of the treatment market Coya seeks with COYA 302. QALSODY news is the relevant signal, not Biogen’s overall sales, which also include its broad multiple-sclerosis portfolio.
Ionis Pharmaceuticals developed QALSODY, an ALS medicine addressing patients Coya seeks to treat with COYA 302, while Biogen handles its worldwide commercialization. For this overlap, watch QALSODY rather than Ionis’s total revenue across its marketed medicines and other activities.
uniQure’s ALS gene-therapy development competes with Coya’s COYA 302 for future treatment use. Its ALS program news is the relevant comparison, rather than its separate agreement to license and supply HEMGENIX to CSL Behring.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy’s report will show how it is advancing the abatacept biosimilar for COYA 302 and preparing for ALS commercialization, both of which shape Coya’s development path and potential collaboration income.
Look for updates on development and supply of the component, alongside preparations to commercialize COYA 302. Progress on both fronts would support the supply and partnership path Coya relies on, which underpins potential milestones and royalties; delays would leave Coya’s trials and prospective income more exposed to its partner.
Biogen Inc. earningsBIIB
Biogen’s QALSODY updates will show whether patients in the drug’s genetic subset of ALS are taking up an approved treatment, a signal about the market Coya hopes to enter.
Look for Biogen’s disclosures about QALSODY use and access, not its overall sales. Rising use or improved access would show that some ALS patients and payors are adopting drug treatment, a market Coya would also have to reach; limited use or access would show that approval alone does not ensure broad adoption.
Amylyx Pharmaceuticals, Inc. earningsAMLX
Amylyx Pharmaceuticals’ report will show whether AMX0114’s ALS development is advancing, giving Coya a read on a prospective treatment competing for future use by ALS patients.
Watch AMX0114’s development milestones and trial progress, not Amylyx’s past ALS product sales. Advancement would add a future treatment option competing for patients with COYA 302; delay or stalling would reduce that pipeline competition, but would not prove patients will choose Coya’s therapy.
Coya Therapeutics, Inc. earningsThis company
Coya Therapeutics has no product-sales revenue, so this report will show how much cash its clinical development uses and whether payments from Dr. Reddy’s offset some of that spending.
Read cash used in operating activities alongside research and development spending, and distinguish collaboration revenue tied to milestones from other revenue. Controlled cash use with collaboration payments would indicate more room to keep development moving; rising cash outflow without milestone support would point to an earlier need for financing or program cuts.
